The Company’s public offering closed on July 2, 2021 and was conducted pursuant to a registration statement filed with the SEC on June 25, 2021 and a final prospectus dated June 29, 2021. The Complaint alleges that the Company failed to disclose that the Food and Drug Administration had placed a clinical hold on the IND applications for its two candidate products, which information the Company had recieved prior to the filing of the Registration Statement and Prospectus issued in connection with its June 2021 public offering.